top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
The children's vaccine initiative : achieving the vision / / Violaine S. Mitchell, Nalini M. Philipose, and Jay P. Sanford, editors ; Committee on the Children's Vaccine Initiative : Planning Alternative Strategies Toward Full U.S. Participation, Division of International Health, Institute of Medicine
The children's vaccine initiative : achieving the vision / / Violaine S. Mitchell, Nalini M. Philipose, and Jay P. Sanford, editors ; Committee on the Children's Vaccine Initiative : Planning Alternative Strategies Toward Full U.S. Participation, Division of International Health, Institute of Medicine
Edizione [1st ed.]
Pubbl/distr/stampa Washington, D.C., : National Academy Press, 1993
Descrizione fisica 1 online resource (xiii, 221 pages) : illustrations
Disciplina 614.4/7/083
Altri autori (Persone) SanfordJay P. <1928->
MitchellViolaine S
PhiliposeNalini M
Soggetto topico Vaccination of children
Vaccines
Immunization of children
Vaccination
Children
Infants
Immunization Programs
Child
Immunization Schedule
Infant
ISBN 9786610196012
9781280196010
1280196017
9780309585835
030958583X
9780585143521
0585143528
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto The Children's Vaccine Initiative -- Copyright -- Preface -- Acknowledgments -- Contents -- 1 Executive Summary -- THE CHILDREN'S VACCINE INITIATIVE -- THE INSTITUTE OF MEDICINE REPORT -- COMMITTEE FINDINGS -- Resources and Infrastructure -- Vaccine Demand and Supply -- Demand -- Supply -- Innovation -- Investing in New and Improved Vaccines -- Stages of Vaccine Development -- Pilot Production -- Clinical Trials -- Scaleup and Large-Scale Manufacture -- Technology Transfer -- A STRATEGY TO ENHANCE U.S. PARTICIPATION -- NOTE -- REFERENCE -- 2 Why a Children's Vaccine Initiative? -- PROGRESS TOWARD UNIVERSAL CHILDHOOD IMMUNIZATION -- Limits of the Expanded Program on Immunization -- THE CHILDREN'S VACCINE INITIATIVE -- Characteristics of CVI Vaccines -- Vaccines Should Be Single Dose -- Vaccines Should Be Administered Near Birth -- Vaccines Should Be Combined in Novel Ways -- Vaccines Should Be Heat Stable -- Vaccines Should Be Effective Against Additional Diseases -- Vaccines Should Be Affordable -- Concerns About the CVI -- RELEVANCE OF THE CVI TO U.S. IMMUNIZATION EFFORTS -- Status of Immunization Efforts in the United States -- A Role for the CVI in the United States -- REFERENCES -- 3 Resources and Infrastructure -- RESOURCES IN THE UNITED STATES -- U.S. Federal Agencies and Programs -- U.S. Agency for International Development -- Center for Biologics Evaluation and Research, U.S. Food and Drug Administration -- Centers for Disease Control and Prevention -- U.S. Department of Defense -- National Institutes of Health -- National Vaccine Program -- Other Federal Programs -- U.S. State Vaccine Manufacturers -- Massachusetts -- Michigan -- U.S.-Based Pharmaceutical Firms -- Connaught Laboratories, Inc. -- Lederle-Proxis Biologicals -- Merck & -- Co., Inc. -- SmithKline Beecham -- Wyeth-Ayerst -- Development-Stage Companies.
North American Vaccine -- MedImmune -- Univax Biologics, Inc. -- Nongovernmental Organizations -- The Children's Defense Fund -- March of Dimes Birth Defects Foundation -- Rockefeller Foundation -- Rotary Foundation -- INTERNATIONAL RESOURCES -- Multilateral Organizations -- Pan American Health Organization -- PAHO Revolving Fund -- SIREVA Project -- United Nations Development Program -- United Nations Children's Fund -- Vaccine Independence Initiative -- World Bank -- World Health Organization -- Expanded Program on Immunization -- Program for Vaccine Development -- Children's Vaccine Initiative -- Public-Sector Resources -- Private-Sector Resources -- Nongovernmental Organizations -- Task Force for Child Survival and Development -- Save the Children Fund -- REFERENCES -- 4 Vaccine Demand and Supply -- GLOBAL DEMAND AND SUPPLY -- Demand -- Regional Demand -- Supply -- Procurement -- Innovation -- DEMAND AND SUPPLY IN THE UNITED STATES -- Demand -- Supply -- Pricing -- Vaccine Innovation -- NOTE -- REFERENCES -- 5 Investing in New and Improved Vaccines -- MARKET CONSIDERATIONS -- Market Size -- Intellectual Property -- Patent Rights and Limitations -- Patents and Vaccines -- Infringement -- LIABILITY -- REFERENCES -- 6 Stages of Vaccine Development -- PRIORITY SETTING -- BASIC AND APPLIED RESEARCH -- CLINICAL EVALUATION -- LICENSURE -- PRODUCTION -- Pilot Production -- ScaleUp and Full-Scale Manufacture -- Vaccine Production in Developing Countries -- RECOMMENDATIONS FOR USE -- PROCUREMENT -- DISTRIBUTION AND DELIVERY -- SURVEILLANCE -- Immunization Status -- Monitoring Effectiveness of Vaccines -- Adverse Reactions -- Setting Priorities for Vaccine Use and New Vaccines -- REFERENCES -- 7 A Strategy to Enhance U.S. Participation in the Children's Vaccine Initiative -- A NATIONAL VACCINE AUTHORITY -- Mission -- Functions.
Setting Priorities and Product Characterization -- Basic Research -- Applied Research and Exploratory Development -- Intellectual Property Rights -- Product Development -- Clinical Evaluation -- Regulation -- Manufacture -- Procurement -- Monitoring and Evaluation -- Management and Organization -- Funding -- Location -- Points to Consider for Locating the CVI in an Existing Federal Agency -- Options -- U.S. Agency for International Development -- Centers for Disease Control and Prevention -- U.S. Department of Defense -- U.S. Food and Drug Administration -- National Institutes of Health -- The National Vaccine Program -- Independent Organization -- NOTE -- REFERENCES -- Appendixes -- A Relevant Intellectual Property Rights Law -- PATENTS -- Rights and Limitations -- Infringement -- Potential Barriers and Incentives -- First-to-File Versus First-to-Invent -- Backlog in the Patent and Trademark Office -- Costs -- Disclosure to Government Agencies -- Relevant Legislation and Terminology -- Drug Price Competition and Patent Term Restoration Act of 1984 (P.L. 98-417) -- Omnibus Trade and Competitiveness Act (P.L. 100-418) -- Grace Period -- Orphan Drug Act of 1983 (P.L. 99-91) -- Patent and Trademark Amendments of 1980 (P.L 96-517) -- Experimental Use Exception -- TRADE SECRETS (KNOW-HOW) -- Definition -- Confidentiality -- Rights of the Trade Secret Owner -- Rights Against Individuals in Privity -- Protection by Contract -- Implied Contract/Special Relationships -- Rights Against Third Parties -- Additional Rights of a Trade Secret Owner -- Rights to Use Another's Trade Secrets -- REFERENCES -- B National Vaccine Injury Compensation Program -- DEFINITION AND PURPOSE -- BACKGROUND -- FILING A CLAIM UNDER NVICP -- KEY CHARACTERISTICS -- REFERENCES -- C Regulatory Aspects of Vaccine Development, Manufacture, and Distribution -- THE LICENSURE PROCESS.
POSTLICENSING -- Manufacture -- Distribution -- THE DRUG EXPORT AMENDMENTS ACT OF 1986 -- REFERENCES -- D Strategies for Achieving Full U.S. Participation in the Children's Vaccine Initiative -- STRATEGY 1: RETAIN THE CURRENT SYSTEM -- Option 1: Increased Funding for CVI Vaccine Research -- Contribution to the Global CVI -- Option 2: Purchase Existing Vaccines -- Contribution to the Global CVI -- Option 3: Improve Vaccine Delivery -- Contribution to the Global CVI -- STRATEGY 2: FORGING NEW PARTNERSHIPS BETWEEN THE PUBLIC AND PRIVATE SECTORS -- Option 1: Broker CVI R& -- D and Pilot Manufacture -- Contribution to the Global CVI -- Option 2: Develop an Entity with CVI-Related R& -- D and Pilot Manufacturing Capabilities -- Contribution to the Global CVI -- STRATEGY 3: EMBARK ON A PUBLIC-SECTOR MODEL -- Contribution to the Global CVI -- E Public Health Service Act (1944) -- PUBLIC LAWS-CH. 373-JULY 1, 1944 PART F-BIOLOGICAL PRODUCTS Regulation of Biological Products -- Interference With Officers -- Penalties for Offenses -- F National Vaccine Program Legislation -- TITLE XXI-VACCINES SUBTITLE 1-NATIONAL VACCINE PROGRAM -- Establishment -- Program Responsibilities -- Plan -- Report -- National Vaccine Advisory Committee -- Authorizations -- G Immunization Schedules -- H Historical Record of Vaccine Product License Holders in the United States -- I Working Group Participants June 11-13, 1992 -- NOTES -- J Committee and Staff Biographies -- K Acronyms.
Record Nr. UNINA-9910970771503321
Washington, D.C., : National Academy Press, 1993
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Plotkin's vaccines / / Stanley A. Plotkin, Walter A. Orenstein, Paul A. Offit
Plotkin's vaccines / / Stanley A. Plotkin, Walter A. Orenstein, Paul A. Offit
Edizione [Seventh edition.]
Pubbl/distr/stampa Philadelphia, PA : , : Elsevier, , [2018]
Descrizione fisica 1 online resource (xxi, 1644 pages) : illustrations (chiefly color), color maps, portraits (some color)
Disciplina 615.3/72
Soggetto topico Immunization
Vaccines
Vaccination
Immunization Programs
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto A short history of vaccination -- Vaccine immunology -- Correlates of protection -- The vaccine industry -- Vaccine manufacturing -- Evolution of adjuvants across the centuries -- Vaccine additives and manufacturing residuals in vaccines licensed in the united states -- Passive immunization -- General immunization practices -- Adenovirus vaccines -- Anthrax vaccines -- Biodefense and special pathogen vaccines -- Cancer vaccines -- Cholera vaccines -- Combination vaccines -- Cytomegalovirus vaccines -- Dengue vaccines -- Diarrhea caused by bacteria -- Diphtheria toxoid -- Ebola vaccines -- Enterovirus 71 -- Epstein-Barr virus vaccines -- Haemophilus influenzae type b vaccines -- Hepatitis A vaccines -- Hepatitis B vaccines -- Hepatitis C vaccines -- Hepatitis E vaccines -- Herpes simplex virus vaccines -- Human immunodeficiency virus vaccines -- Human papillomavirus vaccines -- Inactivated influenza vaccines -- Influenza vaccine--live -- Japanese encephalitis vaccines -- Lyme disease vaccines -- Malaria vaccines -- Maternal immunization -- Measles vaccines -- Meningococcal capsular group A, C, W, and Y conjugate vaccines -- Meningococcal capsular group B vaccines -- Mumps vaccines -- Noninfectious disease vaccines -- Norovirus vaccines -- Parasitic disease vaccines -- Pertussis vaccines -- Plague vaccines -- Pneumococcal conjugate vaccine and pneumococcal common protein vaccines -- Pneumococcal polysaccharide vaccines -- Poliovirus vaccine-inactivated -- Poliovirus vaccine-live -- Rabies vaccines -- Respiratory syncytial virus vaccines -- Rotavirus vaccines -- Rubella vaccines -- Smallpox and vaccinia -- Staphylococcus aureus vaccines -- Streptococcus group a vaccines -- Streptococcus group B vaccines -- Tetanus toxoid -- Tickborne encephalitis vaccines -- Tuberculosis vaccines -- Typhoid fever vaccines -- Varicella vaccines -- Yellow fever vaccines -- Zika virus -- Zoster vaccines -- Technologies for making new vaccines -- Development of gene-based vectors for immunization -- Technologies to improve immunization -- Vaccination of immunocompromised hosts -- Vaccination of human immunodeficiency virus-infected persons -- Vaccines for international travel -- Vaccines for healthcare personnel -- Immunization in the united states -- Immunization in Europe -- Immunization in the Asia-Pacific region -- Immunization in developing countries -- Community protection -- Economic analyses of vaccine policies -- Regulation and testing of vaccines -- Regulation of vaccines in Europe -- Regulation of vaccines in low- and middle-income countries -- Vaccine safety -- Legal issues -- Ethics.
Record Nr. UNINA-9910583080903321
Philadelphia, PA : , : Elsevier, , [2018]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Plotkin's vaccines /...
Suivi des inégalités en matière de vaccination : manuel pratique / / Organisation mondiale de la Santé
Suivi des inégalités en matière de vaccination : manuel pratique / / Organisation mondiale de la Santé
Pubbl/distr/stampa Genève : , : Organisation mondiale de la Santé, , 2021
Descrizione fisica 1 ressource en ligne (viii, 74 pages)
Soggetto topico Immunization Programs
Socioeconomic Factors
National Health Programs
Health Priorities
Programmes de vaccination
Facteurs socioéconomiques
Programmes nationaux de santé
Priorités en santé
ISBN 9789240022317
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione fre
Record Nr. UNISA-996486770803316
Genève : , : Organisation mondiale de la Santé, , 2021
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Suivi des inégalités en matière de vaccination : manuel pratique / / Organisation mondiale de la Santé
Suivi des inégalités en matière de vaccination : manuel pratique / / Organisation mondiale de la Santé
Edizione [1st ed.]
Pubbl/distr/stampa Genève : , : Organisation mondiale de la Santé, , 2021
Descrizione fisica 1 ressource en ligne (viii, 74 pages)
Soggetto topico Immunization Programs
Socioeconomic Factors
National Health Programs
Health Priorities
Programmes de vaccination
Facteurs socioéconomiques
Programmes nationaux de santé
Priorités en santé
ISBN 9789240022317
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione fre
Nota di contenuto Intro -- Foreword -- Acknowledgements -- Abbreviations and acronyms -- Introduction -- About this resource -- Equity Reference Group for Immunization -- Step 1: Determine scope of monitoring -- Overview -- A. Decide on the target population -- b. Identify relevant immunization indicators -- c. Identify relevant dimensions of inequality -- Step 2: Obtain data -- Overview -- A. Conduct data source mapping -- B. Determine whether sufficient data are currently available -- Step 3: Analyse data -- Overview -- A. Prepare disaggregated data -- B. Calculate summary measures of inequality -- Step 4: Report results -- Overview -- A. Define the purpose of reporting and the target audience -- B. Select the scope of reporting -- C. Define the technical content -- D. Decide upon methods of presenting data -- E. Adhere to best practices of reporting -- Step 5: Knowledge translation -- Overview -- Identify priority areas for action -- Integrate equity considerations into immunization programmes and policies -- Identify opportunities for intersectoral collaboration -- Appendix 1. Additional resources -- Appendix 2. Monitoring, Evaluation and Review Framework -- Appendix 3. Double disaggregation -- Appendix 4. Data sources for immunization coverage -- Appendix 5. Overcoming limited data availability -- Appendix 6. Complex measures of inequality -- Appendix 7. Multiple regression analysis and compounded vulnerability -- Appendix 8. Case study: reporting inequalities in immunization -- Glossary.
Record Nr. UNINA-9910591156703321
Genève : , : Organisation mondiale de la Santé, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui